Blockade of dopamine D 3 but not D 2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: Implications for schizophrenia and its treatment

International Journal of Neuropsychopharmacology

Volumn 15, Issue 4, 2012, Pages 471-484

  Watson, David J G ^a   Marsden, Charles A ^a   Millan, Mark J ^b   Fone, Kevin C F ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

D 2 receptors; D 3 receptors; Dopamine; object recognition; post weaning social isolation; schizophrenia

Indexed keywords

3 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINYL]METHYLINDOLE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; L 741 626; N [4 (8 CYANO 1,3A,4,9B TETRAHYDRO 3H BENZOPYRANO[3,4 C]PYRROLE 2 YL0 BUTYL] (4 PHENYL)BENZAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; S 33084; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MALE; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PUP (RODENT); RAT; SCHIZOPHRENIA; SOCIAL ISOLATION;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; MALE; MEMORY DISORDERS; MOTOR ACTIVITY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECOGNITION (PSYCHOLOGY); SOCIAL ISOLATION; WEANING;

EID: 84862655653     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000435     Document Type: Article

References (97)

1. Ashby CR, Minabe Y, Stemp G, Hagan JJ, et al. (2000). Acute and chronic administration of the selective D-3 receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Journal of Pharmacology and Experimental Therapeutics 294, 1166-1174. (Pubitemid 30666873)
2. Bakshi VP, Swerdlow NR, Braff DL, Geyer MA (1998). Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine. Biological Psychiatry 43, 436-445. (Pubitemid 28172388)
3. Bianchi M, Fone KCF, Azmi N, Heidbreder CA, et al. (2006). Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus. European Journal of Neuroscience 24, 2894-2902. (Pubitemid 44813840)
4. Bianchi M, Fone KCF, Shah AJ, Atkins AR, et al. (2009a). Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats. European Neuropsychopharmacology 19, 778-790.
5. Bianchi M, Shah AJ, Fone KCF, Atkins AR, et al. (2009b). Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse 63, 359-364.
6. Boulay D, Depoortere R, Perrault G, Borrelli E, et al. (1999). Dopamine D-2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D-2/D-3 receptor agonists. Neuropharmacology 38, 1389-1396. (Pubitemid 29333155)
7. Bouthenet ML, Souil E, Martres MP, Sokoloff P, et al. (1991). Localization of dopamine D3 receptor messenger RNA in the rat brain using in situ hybridization histochemistry-comparision with dopamine D2 receptor messenger. Brain Research 564, 203-219.
8. Bradley SR, Lameh J, Ohrmund L, Son T, et al. (2010). AC-260584, an orally bioavailable M-1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58, 365-373.
9. Canto CB, Wouterlood FG, Witter MP (2008). What does the anatomical organization of the entorhinal cortex tell us? Neural Plasticity, 1-18.
10. Cilia J, Cluderay JE, Robbins MJ, Reavill C, et al. (2005). Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist. Psychopharmacology (Berlin) 182, 214-219. (Pubitemid 41464614)
11. Clemett DA, Cockett MI, Marsden CA, Fone KCF (1998). Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine(7) receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. Journal of Neurochemistry 71, 1271-1279. (Pubitemid 28390282)
12. Clifford JJ, Waddington JL (1998). Heterogeneity of behavioural profile between three new putative selective D-3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology 136, 284-290. (Pubitemid 28143178)
13. Daly SA, Waddington JL (1993). Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other D-2-like agonists. Neuropharmacology 32, 509-510. (Pubitemid 23161562)
14. Del Arco A, Zhu SW, Terasmaa A, Mohammed AH, et al. (2004). Hyperactivity to novelty induced by social isolation is not correlated with changes in D2 receptor function and binding in striatum. Psychopharmacology 171, 148-155. (Pubitemid 38134651)
15. Dere E, Huston JP, De Souza Silva MA (2007). The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neuroscience and Biobehavioral Reviews 31, 673-704. (Pubitemid 46670336)
16. Diaz J, Levesque D, Lammers CH, Griffon N, et al. (1995). Phenotypical characterisation of neurons expressing the dopamine D-3 receptor in the rat brain. Neuroscience 65, 731-745.
17. Diaz J, Pilon C, Le Foll B, Gros C, et al. (2000). Dopamine D-3 receptors expressed by all mesencephalic dopamine neurons. Journal of Neuroscience 20, 8677-8684.
18. Diaz J, Ridray S, Mignon V, Griffon N, et al. (1997). Selective expression of dopamine D-3 receptor mRNA in proliferative zones during embryonic development of the rat brain. Journal of Neuroscience 17, 4282-4292. (Pubitemid 27220619)
19. Ennaceur A, Delacour J (1988). A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behavioural Brain Research 31, 47-59.
20. Ennaceur A, Neave N, Aggleton JP (1997). Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix. Experimental Brain Research 113, 509-519. (Pubitemid 27140274)
21. Floresco SB, Magyar O, Ghods-Sharifi S, Vexelman C, et al. (2006). Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology 31, 297-309. (Pubitemid 43113395)
22. Fone KC, Shalders K, Fox ZD, Arthur R, et al. (1996). Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology (Berlin) 123, 346-352.
23. Fone KCF (2008). An update on the role of the 5-hydroxytryptamine(6) receptor in cognitive function. Neuropharmacology 55, 1015-1022.
24. Fone KCF, Porkess MV (2008). Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews 32, 1087-1102.
25. Gaskin S, Tremblay A, Mumby DG (2003). Retrograde and anterograde object recognition in rats with hippocampal lesions. Hippocampus 13, 962-969. (Pubitemid 38100745)
26. Gentsch C, Lichtsteiner M, Feer H (1982). Behavioural comparisons between individually-and group-housed male rats: effects of novel environments and diurnal rhythm. Behavioural Brain Research 6, 93-100. (Pubitemid 12007161)
27. Glickstein SB, DeSteno DA, Hof PR, Schmauss C (2005). Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cerebral Cortex 15, 1016-1024. (Pubitemid 40848070)
28. Gould TJ, Rowe WB, Heman KL, Mesches MH, et al. (2002). Effects of hippocampal lesions on patterned motor learning in the rat. Brain Research Bulletin 58, 581-586.
29. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, et al. (2010). Blockade of [C-11](+)-PHNO binding in human subjects by the dopamine D-3 receptor antagonist ABT-925. International Journal of Neuropsychopharmacology 13, 273-287.
30. Green MF (2006). Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. Journal of Clinical Psychiatry 67, 3-8. (Pubitemid 44369648)
31. Guillin O, Diaz J, Carroll P, Griffon N, et al. (2001). BDNF controls dopamine D-3 receptor expression and triggers behavioural sensitization. Nature 411, 86-89. (Pubitemid 32428194)
32. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, et al. (1997). Mesolimbic dopamine D-3 receptors and use of antipsychotics in patients with schizophrenia-a postmortem study. Archives of General Psychiatry 54, 225-232. (Pubitemid 27132051)
33. Gyertyan I, Saghy K, Laszy J, Elekes O, et al. (2008). Subnanomolar dopamine D-3 receptor antagonism coupled to moderate D-2 affinity results in favourable antipsychoticlike activity in rodent models: II. Behavioural characterisation of RG-15. Naunyn-Schmiedebergs Archives of Pharmacology 378, 529-539.
34. Heidbreder CA, Newman AH (2010). Current perspectives on selective dopamine D-3 receptor antagonists as pharmacotherapeutics for addictions and related disorders. Annals of the New York Academy of Science 1187, 4-34.
35. Herroelen L, Debacker JP, Wilczak N, Flamez A, et al. (1994). Autoradiographic distribution of D-3-type dopamine receptors in human brain using [H-3] 7-hydroxy-N,N-di-N-propyl-2-aminotetralin. Brain Research 648, 222-228.
36. Ilani T, Ben-Shachar D, Strous RD, Mazor M, et al. (2001). A peripheral marker for schizophrenia: increased levels of D-3 dopamine receptor mRNA in blood lymphocytes. Proceedings of the National Academy of Sciences USA 98, 625-628. (Pubitemid 32105093)
37. Jones CA, Brown AM, Auer DP, Fone KCF (2011). The mGluR2/3 agonist LY379268 reverses post-weaning social isolation induced recognition memory deficits in the rat. Psychopharmacology 214, 269-283.
38. Joyce JN, Millan MJ (2005). Dopamine D-3 receptor antagonists as therapeutic agents. Drug Discovery Today 10, 917-925. (Pubitemid 40922790)
39. Joyce JN, Millan MJ (2007). Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Current Opinion in Pharmacology 7, 100-105. (Pubitemid 46238043)
40. Keefe RSE, Bilder RM, Davis SM, Harvey PD, et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 64, 633-647. (Pubitemid 46878665)
41. King M, Spicer C, Sleight A, Marsden C, et al. (2009a). Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-HT(6) receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task. Psychopharmacology 202, 111-123.
42. King MV, Seeman P, Marsden CA, Fone KCF (2009b). Increased dopamine D-2(high) receptors in rats reared in social isolation. Synapse 63, 476-483.
43. King MV, Sleight AJ, Woolley ML, Topham IA, et al. (2004). 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47, 195-204. (Pubitemid 38824643)
44. Kosiorek P, Hryniewicz A, Bialuk I, Zawadzka A, et al. (2003). Cannabinoids alter recognition memory in rats. Polish Journal of Pharmacology 55, 903-910. (Pubitemid 37540888)
45. Lacroix LP, Ceolin L, Zocchi A, Varnier G, et al. (2006). Selective dopamine D-3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. Journal of Neuroscience Methods 157, 25-31. (Pubitemid 44287068)
46. Lacroix LP, Hows MEP, Shah AJ, Hagan JJ, et al. (2003). Selective antagonism at dopamine D-3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28, 839-849.
47. Lapiz MD, Mateo Y, Parker T, Marsden C (2000). Effects of noradrenaline depletion in the brain on response on novelty in isolation-reared rats. Psychopharmacology (Berlin) 152, 312-320.
48. Lapiz MDS, Fulford A, Muchimapura S, Mason R, et al. (2003). Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission. Neuroscience and Behavioral Physiology 33, 13-29. (Pubitemid 36230868)
49. Laszy J, Laszlovszky I, Gyertyan I (2005). Dopamine D-3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179, 567-575. (Pubitemid 40674757)
50. Lesage A, Steckler T (2010). Metabotropic glutamate mGlu(1) receptor stimulation and blockade: therapeutic opportunities in psychiatric illness. European Journal of Pharmacology 639, 2-16.
51. Levine JB, Youngs RM, MacDonald ML, Chu M, et al. (2007). Isolation rearing and hyperlocomotion are associated with reduced immediate early gene expression levels in the medial prefrontal cortex. Neuroscience 145, 42-55. (Pubitemid 46227721)
52. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, et al. (1995). Neonatal excitotoxic hippocampal damage in rats causes post pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122, 35-43.
53. Loiseau F, Millan MJ (2009). Blockade of dopamine D-3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D-1 receptor agonists, but not of D-2 antagonists. European Neuropsychopharmacology 19, 23-33.
54. Micale V, Cristino L, Tamburella A, Petrosino S, et al. (2010). Enhanced cognitive performance of dopamine D3 receptor 'knock-out' mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacological Research 61, 531-536.
55. Millan MJ, Brocco M (2008). Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D-3 >D-2 antagonist, S33138. Therapie 63, 187-229.
56. Millan MJ, Buccafusco JJ, Loiseau F, Watson DJG, et al. (2011). The dopamine D3 receptor anatagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. International Journal of Neuropsychopharmacology 13, 1035-1051.
57. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, et al. (2000a). S33084, a novel, potent, selective, and competitive antagonist at dopamine D-3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. Journal of Pharmacology and Experimental Therapeutics 293, 1063-1073. (Pubitemid 30417877)
58. Millan MJ, Di Cara B, Dekeyne A, Panayi F, et al. (2007). Selective blockade of dopamine D-3 vs. D-2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. Journal of Neurochemistry 100, 1047-1061. (Pubitemid 46213928)
59. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, et al. (2000b). S33084, a novel, potent, selective, and competitive antagonist at dopamine D-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. Journal of Pharmacology and Experimental Therapeutics 293, 1048-1062. (Pubitemid 30417876)
60. Millan MJ, La Cour CM, Novi F, Maggio R, et al. (2008a). S33138 [N-[4-[2-[(3aS, 9bR)-8-cyano-1,3a,4,9btetrahydro[ 1]-benzopyrano[3,4-c] pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D-3 vs. D-2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. Journal of Pharmacology and Experimental Therapeutics 324, 587-599. (Pubitemid 351185866)
61. Millan MJ, Loiseau F, Dekeyne A, Gobert A, et al. (2008b). S33138 (N-[4-[2-[(3aS, 9bR)-8-cyano-1,3a,4,9btetrahydro[1]benzopyrano[3,4-c]pyrrol- 2(3H)-yl)-e thyl]phenyl-acetamide), a preferential dopamine D-3 vs. D-2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. Journal of Pharmacology and Experimental Therapeutics 324, 1212-1226. (Pubitemid 351397860)
62. Millan MJ, Seguin L, Gobert A, Cussac D, et al. (2004). The role of dopamine D-3 compared with D-2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 174, 341-357. (Pubitemid 39044292)
63. Millan MJ, Svenningsson P, Ashby CR, Hill M, et al. (2008c). S33138 [N-[4-[2-[(3aS, 9bR)-8-cyano-1,3a,4, 9b-tetrahydro[1]benzopyrano[3,4-c]pyrrol- 2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D-3 vs. D-2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. Journal of Pharmacology and Experimental Therapeutics 324, 600-611. (Pubitemid 351185867)
64. Moser PC, Bergis OE, Jegham S, Lochead A, et al. (2002). SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. Journal of Pharmacology and Experimental Therapeutics 302, 731-741. (Pubitemid 34787242)
65. Ouagazzal AM, Creese I (2000). Intra-accumbens infusion of D-3 receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacology Biochemistry and Behavior 67, 637-645. (Pubitemid 32103576)
66. Park WK, Jeong D, Cho H, Lee SJ, et al. (2005). KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Pharmacology Biochemistry and Behavior 82, 361-372. (Pubitemid 41727948)
67. Pascoli V, Boer-Saccomani C, Hermant JF (2009). H-3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval. Psychopharmacology 202, 141-152.
68. Patil ST, Zhang L, Martenyi F, Lowe SL, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 13, 1102-1107. (Pubitemid 47517511)
69. Porsolt RD, Moser PC, Castagne V (2010). Behavioral indices in antipsychotic drug discovery. Journal of Pharmacology and Experimental Therapeutics 333, 632-638.
70. Prickaerts J, Sik A, van der Staay FJ, de Vente J, et al. (2005). Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition vs. consolidation. Psychopharmacology 177, 381-390. (Pubitemid 40228285)
71. Pritchard LM, Logue AD, Taylor BC, Ahlbrand R, et al. (2006). Relative expression of D3 dopamine receptor and alternative splice variant D3nf rnRNA in high and low responders to novelty. Brain Research Bulletin 70, 296-303. (Pubitemid 44486559)
72. Pritchard LM, Newman AH, McNamara RK, Logue AD, et al. (2007). The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacology Biochemistry and Behavior 86, 718-726. (Pubitemid 46829327)
73. Rabiner EA, Slifstein M, Nobrega J, Plisson C, et al. (2009). In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63, 782-793.
74. Reavill C, Taylor SG, Wood MD, Ashmeade T, et al. (2000). Pharmacological actions of a novel, high-affinity, and selective human dopamine D-3 receptor antagonist, SB-277011-A. Journal of Pharmacology and Experimental Therapeutics 294, 1154-1165. (Pubitemid 30666872)
75. Renou J, De Luca V, Zai CC, Bulgin N, et al. (2007). Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry 12, 1058-1060. (Pubitemid 350191368)
76. Richtand NM,Woods SC, Berger SP, Strakowski SM (2001). D3 dopamine receptor, behavioral sensitization, and psychosis. Neuroscience and Biobehavioral Reviews 25, 427-443. (Pubitemid 32879299)
77. Rutten K, Prickaerts J, Blokland A (2006). Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiology of Learning and Memory 85, 132-138. (Pubitemid 43247839)
78. Sahakian BJ, Robbins TW, Iversen SD (1977). Effects of isolation rearing on exploration in rat. Animal Learning & Behavior 5, 193-198. (Pubitemid 8132710)
79. Sautel F, Griffon N, Sokoloff P, Schwartz JC, et al. (1995). Nafadotride, a potent preferential dopamine D-3 receptor antagonist, activates locomotion in rodents. Journal of Pharmacology and Experimental Therapeutics 275, 1239-1246. (Pubitemid 26130635)
80. Scaccianoce S, Del Bianco P, Paolone G, Caprioli D, et al. (2006). Social isolation selectively reduces hippocampal brain-derived neurotrophic factor without altering plasma corticosterone. Behavioural Brain Research 168, 323-325. (Pubitemid 43201951)
81. Schubert MI, Porkess MV, Dashdorj N, Fone KCF, et al. (2009). Effects of social isolation rearing on the limbic brain: a combined behavioral and magnetic resonance imaging volumetriy study in rats. Neuroscience 159, 21-30.
82. Schwartz JC, Diaz J, Pilon C, Sokoloff P (2000). Possible implications of the dopamine D-3 receptor in schizophrenia and in antipsychotic drug actions. Brain Research Reviews 31, 277-287. (Pubitemid 30136182)
83. Seeman P, Schwarz J, Chen JF, Szechtman H, et al. (2006). Psychosis pathways converge via D2(High) dopamine receptors. Synapse 60, 319-346. (Pubitemid 44134353)
84. Sesack SR, Grace AA (2010). Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 35, 27-47.
85. Sigala S, Missale C, Spano P (1997). Opposite effects of dopamine D-2 and D-3 receptors on learning memory in the rat. European Journal of Pharmacology 336, 107-112. (Pubitemid 27464853)
86. Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, et al. (2004). Selective blockade of D-3 dopamine receptors enhances the antiparkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Experimental Neurology 188, 128-138. (Pubitemid 38748811)
87. Smith AG, Neill JC, Costall B (1999). The dopamine D-3/D-2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset. Pharmacology Biochemistry and Behavior 63, 201-211. (Pubitemid 29234098)
88. Sokoloff P, Diaz J, Le Foll B, Guillin O, et al. (2006). The dopamine D-3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS & Neurological Disorders-Drug Targets 5, 25-43. (Pubitemid 43796626)
89. St Onge JR, Floresco SB (2009). Dopaminergic modulation of risk-based decision making. Neuropsychopharmacology 34, 681-697.
90. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, et al. (1998). D-3 dopamine receptor mRNA is widely expressed in the human brain. Brain Research 779, 58-74. (Pubitemid 28039940)
91. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, et al. (2000). Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Molecular Psychiatry 5, 293-300. (Pubitemid 30438405)
92. Winner B, Desplats P, Hagl C, Klucken J, et al. (2009). Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Experimental Neurology 219, 543-552.
93. Winters BD, Saksida LM, Bussey TJ (2008). Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neuroscience and Biobehavioral Reviews 32, 1055-1070.
94. Woolley ML, Marsden CA, Fone KCF (2004). 5-HT6 receptors. Current Drug Targets-CNS and Neurological Disorders 3, 59-79.
95. Woolley ML, Marsden CA, Sleight AJ, Fone KCF (2003). Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology 170, 358-367. (Pubitemid 38010507)
96. Young JW, Powell SB, Risbrough V, Marston HM, et al. (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacology & Therapeutics 122, 150-202.
97. Zhang M, Ballard ME, Kohlhaas KL, Browman KE, et al. (2006). Effect of dopamine D-3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 31, 1382-1392.